Press Releases

10.19.2015

Pfizer’s Inotuzumab Ozogamicin Receives FDA Breakthrough Therapy Designation for Acute Lymphoblastic Leukemia (ALL)

10.14.2015

Pfizer Receives Complete Response Letter from FDA for Oral XELJANZ® (tofacitinib citrate) Supplemental New Drug Application for Moderate to Severe Chronic Plaque Psoriasis

10.13.2015

Pelago Bioscience grants Pfizer Inc. license to the CETSA™ method

10.13.2015

Pfizer and the Union for International Cancer Control Award 20 Grants Totaling $760,000 to Address the Needs of Metastatic Breast Cancer Patients Worldwide

10.09.2015

Pfizer’s Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA® When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate (MCV4) and Tetanus, Diphtheria and Pertussis (Tdap) Vaccines in Adolescents

10.07.2015

Merck KGaA, Darmstadt, Germany, and Pfizer Announce Investigational Immunotherapy Avelumab Receives FDA Fast Track Designation for Metastatic Merkel Cell Carcinoma

10.02.2015

Pfizer Inc. Announces Final Results of Exchange Offers

10.01.2015

Pfizer Completes Acquisition Of Nimenrix And Mencevax From GlaxoSmithKline

09.30.2015

Pfizer Partners with Breast Cancer Leaders to Chronicle the Lives of Women with Metastatic Breast Cancer through the Lenses of Prominent Photographers

09.30.2015

Pfizer Updates 2015 Financial Guidance Solely to Include Hospira Operations In Financial Results From September 3, 2015 Through Year-End 2015

09.30.2015

Is 50 Really the New 30? Your Immune System May Not Think So

09.25.2015

Pfizer Declares 28-Cent Fourth-Quarter 2015 Dividend